Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.39 |
| ▸ | BCHE | P06276 | 2/20 | 0.39 |
| ▸ | ACHE | P22303 | 2/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.38 |
| ▸ | CDC25B | P30305 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | AKT1 | P31749 | 1/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15969169 | 1.00 | LMNA (0.63) | LMNAMAPTHRH4HRH3BCHE | |
| SCHEMBL3590890 | 0.79 | LMNA (0.52) | LMNAHRH4HRH3BCHEACHE | |
| SCHEMBL1269358 | 0.77 | LMNA (1.00) | LMNAMAPTHRH4HRH3BCHE | |
| SCHEMBL971425 | 0.77 | SLC6A2 (0.55) | LMNAHRH4HRH3BCHEACHE | |
| SCHEMBL3031655 | 0.77 | SLC6A2 (0.55) | LMNAHRH4HRH3BCHEACHE | |
| SCHEMBL18844035 | 0.77 | LMNA (1.00) | LMNAMAPTHRH4HRH3BCHE | |
| SCHEMBL971427 | 0.77 | SLC6A2 (0.55) | LMNAHRH4HRH3BCHEACHE | |
| SCHEMBL5708359 | 0.77 | LMNA (1.00) | LMNAMAPTHRH4HRH3BCHE | |
| SCHEMBL10420228 | 0.76 | LMNA (0.54) | LMNAHRH4HRH3BCHEACHE | |
| SCHEMBL19559233 | 0.76 | LMNA (0.54) | LMNAHRH4HRH3BCHEACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2963043-B1 | TETRAHYDROIMIDAZO[1,5-D][1,4]OXAZEPINE DERIVATIVE | EISAI R&D MAN CO LTD (JP) | 2018-05-30 | — | — | EP | disclosed |
| US-9458176-B2 | Tetrahydroimidazo(1,5-D)[1,4]oxazepine derivative | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-10-04 | — | — | US | disclosed |
| EP-2963043-A1 | TETRAHYDROIMIDAZO[1,5-D][1,4]OXAZEPINE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2016-01-06 | — | — | EP | disclosed |
| US-20140243316-A1 | Tetrahydroimidazo(1,5-D)[1,4]Oxazepine Derivative | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243316-A1 | Tetrahydroimidazo(1,5-D)[1,4]Oxazepine Derivative | GRM2, GRM1, GRIA2 | LMNA 4725/4885MAPT 249/4885HRH4 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.